Tianjin Pharma Closes a $20 Million Neuralstem Investment

Tianjin Pharma Group closed its $20 million investment in Neuralstem, a US-China biopharma, a transaction originally announced in September. Neuralstem, which had a market capitalization of $30 million before the transaction, has several central nervous system drug candidates in clinical development, based on its neural stem cell technology. Tianjin said it anticipates forming partnerships with Neuralstem in the future, presumably for China rights to candidates, though no specific deals were disclosed. If Tianjin exercises its conversion rights, it would own 40% of Neuralstem. More details.... Stock Symbol: (NSDQ: CUR) Share this with colleagues: // //